RESEARCH TRIANGLE PARK – T3D Therapeutics has raised $15 million in new financing to fund continued development of its proposed treatment of Alzheimer’s, one that the company says has the potential to slow, stop or reverse the course of the disease

“We believe T3D-959 has the potential to be Alzheimer’s disease remedial, to either slow, stop, or even reverse the course of disease as a single drug therapy,” said Chief Executive Officer John Didsbury in a statement. “Our drug works to overcome aberrant glucose (sugar) and lipid (fat) metabolism in the brain that is inherent in AD. This dysfunctional metabolism causes protein mis-folding which in turn leads to plaques, tangles and inflammation.”

T3D, which has multiple drugs under development, also has received funding support from the National Institute on Aging.

The funding news came shortly after a Chinese firm announced approval of a new Alzheimer’s drug in its home country. Clinical trial is expected in the US next year.

China approves new drug to treat Alzheimer’s; clinical trials planned for 2020 in US

The funding will be used for a Phase 2 clinical trial.

According to the company, it acts in a multi-faceted manner; the drug addresses and improves the most important defects of Alzheimer’s disease that cause the starvation and the strangulation.

T3D’s pipeline

“We are eager to expand our testing of T3D-959 in Alzheimer’s patients in this new Phase 2 study since it uniquely targets mechanisms which we believe underlie the development of the memory deficits in this disorder,” added Warren Strittmatter, Chief Medical Officer of T3D Therapeutics, Emeritus Professor of Neurology at Duke University Medical Center and a Alzheimer’s Association Zenith Award winner.

The trial is expected to begin early next year,

Innovative Alzheimer’s drug developer T3D Therapeutics injects $700K of a debt offering